Paragon 28, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
May 08, 2024 at 04:05 pm EDT
Share
Paragon 28, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported sales was USD 61.08 million compared to USD 52.04 million a year ago. Net loss was USD 15.23 million compared to USD 9.05 million a year ago.
Paragon 28, Inc. is a medical device company. The Company develops, distributes, and sells medical devices in the foot and ankle segment of the orthopedic implant marketplace. Its products and product families include plates and plating systems, screws, staples, and nails to address all foot and ankle procedures, including fracture fixation, forefoot, or hallux valgus, which includes bunion and hammertoe, ankle, flatfoot, or progressive collapsing foot deformity (PCDF), Charcot foot and Ortho biologics. It provides a comprehensive portfolio of solutions that includes surgical implants and disposables, as well as surgical instrumentation. The Companyâs suite of surgical solutions comprises 75 product systems, including approximately 9,200 SKUs, which comprises of approximately 6,800 implants, 1,400 instruments and 1,000 disposable and other SKUs. Its products are available in a variety of sizes and configurations to suit the individual patientâs anatomical and surgical requirements.
PARAGON 28, INC. 
